Table 5.
Viremia in NHPs after challenge infection
| Group | Vaccine | % Positive* (pos./tested) in qRT-PCR | % Positive† (pos./tested) in virus titration | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Days post challenge | Days post challenge | ||||||||
| 3 | 4 | 5 | 10 | 3 | 4 | 5 | 10 | ||
| 1 | YFE-1 | 0 (0/6) | 17 (1/6) | 0 (0/6) | 0 (0/6) | 17 (1/6) | 17 (1/6) | 0 (0/6) | 0 (0/6) |
| 2 | YFE-2E | 0 (0/6) | 0 (0/6) | 0 (0/6) | 0 (0/6) | 17 (1/6) | 0 (0/6) | 0 (0/6) | 0 (0/6) |
| 3 | Mock | 0 (0/2) | 50 (1/2) | 0 (0/2) | 0 (0/2) | 50 (1/2) | 50 (1/2) | 50 (1/2) | 0 (0/2) |
| 4 | Clean | 100 (2/2) | 100 (2/2) | 100 (2/2) | 50 (1/2) | 50 (1/2) | 100 (2/2) | 50 (1/2) | 0 (0/2) |
| 5 | 17DD | 0 (0/4) | 0 (0/4) | 0 (0/4) | 0 (0/4) | 0 (0/4) | 0 (0/4) | 0 (0/4) | 0 (0/4) |
NHP = nonhuman primates; PFU = plaque-forming units; qRT-PCR = real-time quantitative reverse transcription polymerase chain reaction; YFE = yellow fever virus envelope protein.
*
Above the detection limit = 0.4 log10 PFU/mL is considered positive.
†
Above 3.3 log10 copies/mL is considered positive.